ROCKVILLE, Md., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant protein nanoparticle vaccines and adjuvants, today announced its financial results for the third quarter and nine months ended September 30, 2013.
Help employers find you! Check out all the jobs and post your resume.
